Key findings
- US $26000per patient-year for lecanemab (donanemab $15000), drugs that require biweekly IV administration and whose cost-effectiveness has been strongly challenged
- AUC = 0.752for fecal acetic acid, which might discriminate MCI from non-dementia-prone subjects
- 722elders with MCI in a recent review that found VR interventions significantly improved memory, attention and information processing speed even without therapist involvement
- 3 to 12 trillion yenin economic benefits that a diagnostic-therapeutic policy could yield in Japan alone if it suppressed dementia onset by even 10%, by the authors' estimate
Abstract
Dementia affects a huge and growing elderly population; therefore early detection and prevention are critical to public health. However, public health systems have not yet been able to target their at-risk populations in greatest need of preventive treatment, nor to afford the costs of diagnoses and medication for the majority of people who will live with dementia. This article advocates new inexpensive technologies that enable population-wide screening methods to identify those most at risk of dementia, followed by other new technologies that postpone and potentially reverse the dementia onset of these high-risk groups, at tremendous savings to public health systems.
Present diagnostics (typically using MRI, PET, CT tomography, or CSF Cerebrospinal Fluid) are so costly that they cannot be offered to the tens of millions of individuals who might benefit from them. Post-diagnostic pharmaceutical treatments are similarly unaffordable and unavailable for large populations.
Our team of medical policy scholars reviewed a wide range of diagnostic tools with lowest costs and psychological barriers, and affordable non-prescription treatments effective for large elderly populations. For early detection before senescence manifests, we found that non-invasive salivary acetylcholine and lactoferrin, urinary AD7c-NTP, fecal lactic acid and ammonia, or a combination thereof provide predictive value rivalling tomography and other biomarkers at far lower cost. Recently, smartphone and laptop cameras can also be programmed to detect patterns of eye movement associated with dementia risk before symptoms become noticeable. For early prevention and delay of AD onset, subsidizing Cognitive Stimulation Therapy (CST), VR programs, and possibly dietary supplements for at-risk populations will prove tremendously more cost-effective than present approaches.
Acknowledging the need for continuing research, we do not imply that all the technologies and interventions identified here are the final word on the subject, but rather hope to provide a model example of policy design more suitable to population-wide public health approaches to dementia.
Key points: Since dementia affects a huge and growing elderly population, public health and equity require affordable and widely available methods of early detection illustrated by recent research. To detect and prevent dementia, governments and insurers should promote economical non-invasive screening, such as saliva, urine, and fecal analyses. Smartphone and laptop cameras can also detect rapid eye movements that predict dementia in advance, while CST and VR can be used to delay AD, as may Lithium Orotate therapy.
Introduction
Dementia is currently the seventh leading cause of death globally, and a leading cause of disability and dependency among older people.1 For caregivers, dementia poses a double burden, as they lose the loved ones they knew, while trying to deal with their BPSD, ranging from depression and wandering to hallucinations and aggression.2 This engenders caregiver burnout, neglect, and verbal abuse and physical violence against family or patients.3
In addition to psychological and criminological issues, dementia poses a tremendous mushrooming economic burden on states that subsidize care. At present, six percent of most OECD countries’ senior populations express dementia, with Korea and Japan at the high end, near 10 and 12 percent.4 Alzheimer’s International says “The 55 million people with dementia in 2020 will double every 20 years, reaching 78 million in 2030 and 139 million in 2050. The annual global cost of dementia is now above US $1.3 trillion and is expected to rise to US $2.8 trillion by 2030. If global dementia care were a country, it would be the 14th largest economy in the world.”5
However, there is no cure for dementia, once it fully manifests. Standard medical methods of detection tend to be intrusive; standard treatments have limited effectiveness with high costs. To achieve a sustainable aging society, we need a comprehensive strategic framework for dementia care which includes widespread cost-effective prediction and effective prevention. Widespread prediction can now be obtained through simple non-invasive testing at a stage well before the onset of dementia. Targeted prevention can now be achieved by using psycho-physical as well as medical stimuli. New discoveries promise far more cost-effective treatment options. Our team of medical and policy researchers overviewed a wide range of recent developments in the field of dementia, focusing on examples most likely to be useful in standard health screening and practice, to substantially reduce the scale of suffering from dementia for patients, families, and societies alike.
Present Approaches
Present testing methods
Present dementia testing methods center on psychological and medical tests. Psychological tests take time, both for the taker and for the professional administrator. With proper explanation, the Mini-Cog takes 5 minutes, while the Montreal Cognitive Exam (MoCa) and MMSE take 15 minutes. More problematically, these tests presuppose the willingness of patients to submit themselves to dementia examinations; they painfully raise fears or realizations of present dementias, and fail to predict significantly in advance those people likely to contract dementia. So, they require the time (=cost) of medical professionals to administer, and the agreement of potential patients to reserve times to take the exams and submit to self-examination. While they are now used for assigning welfare support or pharmaceutical intervention by identifying the severity of dementia, they only confirm the symptoms suspected by caregivers, but do nothing to predict symptoms yet to arise.
Medical testing tends to rely on brain scans or spinal fluid tests (MRI, PET or CT tomography, and CSF), but these are extremely costly and typically too late; they identify brain conditions or biomarkers after the fact, confirming the disease with little solace for patients and their families. Scanning procedures and CSF lumbar punctures require trained staff, time for processing, and expensive equipment. Each MRI brain scan typically costs hundreds of dollars or Euros; each PET or CT scan costs thousands of dollars or Euros; each Cerebrospinal Fluid (CSF) scan hundreds to thousands of dollars or Euros (to the taxpayers if not to the patient alone). In addition, the time and trouble of making appointments and going to the clinic or hospital can prove prohibitive. So present procedures to diagnose dementia pose such high costs to society that it is impractical to offer scans to large segments of the population at risk.
Present treatment methods
The most widely used treatments for dementia are costly rear-guard efforts to delay symptoms rather than to cure underlying issues. In early stages, lecanemab or donanemab may slow the onset of dementia, while cholinesterase inhibitors like Aricept (Donepezil) increase neurotransmission. In mid-to-late stages, NMDA receptor antagonists like Namenda (Memantine) try to protect brain cells by glutamate regulation. All have side effects, yet none reverse dementia itself.
Newly approved drugs like lecanemab (US $26000/patient-year) and donanemab ($15000/patient-year) require biweekly IV administration, so their cost-effectiveness has been strongly challenged.6 Branded Aricept and Namenda cost thousands of US dollars per patient per year. Their generic counterparts Donepezil and Memantine reduce this to a few hundred dollars per patient/year (in addition to costs of prescription and administration). These latter generic drugs remain the front line of pharmaceutical prescription, but at best delay without fundamentally curing dementia, and with many side-effects. Given our inability to increase geriatric personnel in the future, this doctor/hospital-based system is not affordable, much less sustainable.
Where costs and hurdles of dementia diagnosis can neither meet growing demand nor prove cost-effective, we need new approaches that predict and prevent. By way of analogy, lung cancer and liver cirrhosis are almost impossible to cure, but can be substantially prevented by avoiding consumption of tobacco and alcohol. Similarly, dementia, once manifested, seems almost impossible to cure, so if it can be predicted and prevented, there is every reason to do so. Against the psychological and economic costs of present practices, recent developments offer new possibilities for public health approaches to dementia.
Prediction through Testing
Widespread prediction can now be achieved through simple testing, using saliva, urine, and fecal biomarkers, which reflect central nervous system pathology (such as Amyloid-β accumulation, tau pathology, neuroinflammation, and systemic metabolic alterations) without invasive medical procedures. Recent eye-test technologies for cognitive sensing share a common paradigm characterized by minimal invasiveness, repeatability, and low-cost user-centric implementation, enabling continuous real-world assessment of cognitive function.
Saliva
Many biomarkers are present in saliva, which is painless to extract, and gained public acceptance through years of Covid testing. In saliva, more than Tauß or Aß, acetylcholine and lactoferrin levels are the major indicators of dementia. Early research suggested acetylcholine esterase (AchE, that breaks down the neurotransmitter acetylcholine into choline and acetate) as a simple diagnostic biomarker for dementia.7,8
More recent research demonstrates that salivary lactoferrin (sLF glycoprotein) levels measured by ELISA (Enzyme-Linked Immunosorbent Assay)s were cheaper and more accurate even than AchE assays, outperforming even costly standard CSF indicators in detecting early cognitive loss.9 A burgeoning literature suggests that salivary lactoferrin may become a new standard for non-invasive dementia prediction.10 This is especially good news because sLF detection is not only non-invasive and highly accurate, but also cost-effective.11
Urine
Dementia and cognitive impairment correlate with urinary interleukin-6 signal transducer IL6ST and IL 19, while a primary serotonin metabolite, 5-hydroxyindole acetic acid (5-HIAA) indicates impaired neurotransmission in AD.12 Since it is far cheaper to detect acetic acids than interleukins in urine, an acetic acid test might be used a standard, automated, high-volume lab test.
Even more accurate, urinary AD7c-NTP (Alzheimer-Disease-associated 7c neuronal thread protein) is an extensively investigated biomarker diagnostic of AD. Its levels are substantially higher in mild cognitive impairment and early AD, corresponding with the extent of the disease and cognitive decline. AD7c-NTP is an adequate diagnostic for early diagnosis of AD since it indicates axonal degeneration and neuronal damage.13 Since urine tests are non-invasive and already widely used in public health settings, adding a screening for 5-HIAA acetic acid or for AD7c-NTP protein could prove effective as well as cost-effective.
Feces
Alongside salivary and urine tests, fecal stool tests provide common, non-invasive, inexpensive diagnostic resources. We already noted that salivary acetylcholine and urinary acetic acid correlate with dementia, so it is unsurprising that fecal acetic acid might discriminate MCI from non-dementia-prone subjects (AUC = 0.752).14 Even better, Japanese studies found a combination of higher fecal ammonia and lower lactic acid concentrations was indicative of the presence of dementia, with predictive value rivalling that of other traditional biomarkers of dementia!15
Amyloid and fatty-acid fecal analyses may also assist future diagnostic arsenals, but testing for fecal lactic acid and ammonia would prove far more economical. A combination of non-invasive biomarkers found in saliva, urine, and/or feces could enable probabilistic diagnosis of dementia for large elderly populations at low expense.
Eye-tests
Eye-test technologies are non-invasive (requiring no blood draws nor tissue sampling) thus permitting high-frequency repeated diagnosis. Even before dementia has become noticeable, brains at high risk of dementia process visual data and eye-movements differently: showing more rapid movements and shorter fixation duration, following targets for shorter times, and making more interruptive movements than peers at lower risk.16 These predictive measures open an advance window of time for intervention, unlike measures that only detect AD after the fact.17 Rapid eye movement measurement is easy to conduct, and can diagnose dementias other than Alzheimer's as well, predicting dementia risk in populations.18
Every day, the adult population spends many minutes or hours staring at their smartphones or computer screens. If they simply give permission, their smartphones or computer cameras can readily collect data about the stability of their eye-movements, which can be anonymously compared with data from millions of other individuals, to seek other common denominators in dementia populations. Without using expensive eye-tracking devices,19 smartphone and laptop cameras can now gather eye-tracking data every bit as effectively as professional machines!20 This eye-tracking technology potentially provides a non-invasive, cost-effective, and scalable option for early MCI prediction, improving preventive medicine and contributing to the proactive treatment of cognitive health.21
Cost-effective Treatments
The above mini-review establishes that noninvasive examinations such as of salivary lactoferrin, urinary acetic acid or AD7c-NTP, fecal lactic acid and ammonia, and cell phone or computer-camera detection of unstable rapid eye-movement can identify the 10% of adult population at greatest risk of developing dementia—while it can still be prevented. The next question becomes: What methods are most cost-effective to prevent targeted at-risk populations from developing dementia? New discoveries promise highly cost-effective treatment options. The main candidates here are (1) Cognitive stimulation (CST), (2) VR therapy, and (3) dietary supplements.
Cognitive stimulation therapy (CST)
Targeted prevention can be achieved using psycho-physical as well as medical stimuli. Among countless psycho-social interventions, Cognitive Stimulation Therapy (CST) has proven the most cost-effective.22 CST is the premier non-pharmacological intervention for people with early or mild dementia, improving cognition, communication, confidence, and quality of life.23 CST involves two hours per week of reminiscence (recalling past events), current affairs discussions, word association games, creative arts, physical exercises, and music-based tasks, led by trained facilitators. While few psycho-social interventions have demonstrated effectiveness in RCTs, D’Amico’s24 RCT offers hope for inexpensive social educational interventions effective in the early stages of dementia.25 Periodic CST “booster sessions” have proven particularly effective in lowering the risk of AD.26
The WHO, OECD, and Alzheimer’s International recognize the potential benefits of CST, and the UK’s NHS has incorporated CST in some memory clinics. While most dementia professionals recognize the value of CST, staffing challenges have delayed its widespread use. A small investment in CST staff and education might produce large benefits and savings in terms of future dementia costs.27
Virtual reality (VR) therapies
While CST depends on well-trained staff, modern VR techniques enable staff with little training to help high-risk dementia candidates to prevent dementia from manifesting. VR typically involves interacting with a computer screen or headset,28 programmed to encourage cognitive, physical, or combined cognitive-physical activities to stimulate brain activity. These programs can be provided to participants’ computers and smartphones, or may use cheap headsets whereby users view their own smartphones like goggles. Some studies found that using tablet computers significantly improved MMSE scores as well as sense of well-being.29 VR training interventions have proven effective in boosting memory and visuo-spatial abilities, reducing depression and improving overall well-being in older adults.30 A recent review of 722 elders with MCI found that VR interventions significantly improved memory, attention and information processing speed even without therapist involvement!31 Another review of 19 studies covering 590 participants concluded that almost all studies showed greater improvements in VR intervention groups than in control groups.32
As a growing majority of senior citizens uses smartphones, with time on their hands and strong interest in avoiding dementia, there seems every reason to promote VR programs that boost memory and improve well-being.33 Continuing competition among software developers will produce VR programs ever more effective in delaying the onset of dementia, even among MCI risk groups.
Dietary remediation
It has long been recognized that long-chain Omega-3 fatty-acids, such as DHA and EPA (found in cold-water fatty fish), can help to prevent dementia, while butyrate (a short-chain fatty-acid produced by microbiota fermenting fiber in the gut) can possibly even reverse it.34,35 One recent longitudinal study of 217,122 people found that Omega-3 fatty-acids statistically significantly lowered risk of early onset dementia.36 The histone deacetylase (HDAC) inhibitor sodium butyrate has neuroprotective, anti-oxidative, anti-inflammatory, and Aβ-peptide-lowering effects likely to prevent dementia.37 Higher sodium butyrate levels improved memory and cognitive function not only in mouse models,38 but also in older human populations.39 So Omega-3 fish oil or sodium butyrate supplements might delay or prevent dementia.
For 60 years, lithium has effectively treated bi-polar disorder40 while coincidentally reducing the risk of AD.41 Among other effects,42 lithium inhibits Aβ generation through inhibiting GSK-3α.43 Lithium Orotate reduces amyloid sequestration and effectively increases non-plaque lithium levels in the brain.44,45 Cohort studies show lithium use decreases dementia,46 while RCTs show lithium superior to placebo in reducing MCI/AD.47,48 Meta-analyses show lithium lowers dementia risk49,50 more effectively than donanemab, lecanemab, or aducanumab!51,52 Recent studies showed that lithium deficiency contributes to dementia,53 while oral Lithium Orotate reversed dementia in mice.54
Bipolar Lithium Carbonate prescriptions exceeding 500mg/day pose renal issues, but Lithium Orotate prevents dementia at well-tolerated micro-doses of 3-5mg/day, without toxic side-effects.55 A major Danish study showed that even trace lithium in drinking water inversely correlated with dementia.56 Mounting evidence suggests that Lithium Orotate micro-doses should be a first-line supplement for prevention and reversal of amyloid tangles in the brain.57 Already widely sold over the counter, 3-5mg trace doses of Lithium Orotate are cheaper than potentially synergistic sodium butyrate; both are hundreds of times cheaper than pharmaceuticals.
Discussion
The staggering costs of medicating and caring for dementia patients increase annually. Alzheimer’s Association reports the following statistics for the US (figures may be higher for other countries with more elderly populations):58
- Medical payments in 2025 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated at $384 billion.
- The lifetime cost of care for each person with dementia exceeds $400,000.
- The cost of 11 million unpaid caregivers’ care is valued at another $413.5 billion.
- Care time rises from 150 hours per month for early dementia to 283 hours per month in 8 years.
- Medicaid payments for demented patients exceed 22 times those of non-demented patients.
Significantly, these figures ignore or underestimate the costs of family/caregivers’ health and lost productivity. Moreover, trillions of dollars are held by elders who have or will lose competency to manage these funds. In short, the social and medical costs of caring for dementia are immense.
Public health policies can cost-effectively respond to dementia
Our above review first showed that inexpensive additions to widely used analyses of saliva, urine, or feces, along with programs using phones or computer cameras, can identify individuals at greatest risk of developing dementia. Secondly, inexpensive, non-pharmaceutical methods delay the onset of dementia and may even improve cognitive function, from CST and VR interventions to daily Lithium Orotate and possibly fatty-acid supplements. Yet states, countries, and insurance companies that will later pay the high costs of dementia care and medications have not widely publicized nor promoted these predictive and preventive measures.
In oversimplified comparison, diagnostic MRI, PET, or CSF scans cost a hundred times more than adding another item to proposed urinalysis, fecal scans, or eye-movement diagnoses. Biweekly lecanemab (US $26000/patient-year) or donanemab ($15000/patient-year) cost a hundred times more than VR interventions and Lithium Orotate supplements. Yet this is not a fair comparison, because presently used scans and medications merely confirm the presence of dementia without improving it. Our proposal not only identifies people at risk, but may prevent or possibly cure incipient dementia before it severely manifests. Considering the urgency of dementia countermeasures, a prompt policy shift from post-onset responses to prevention-focused policies is the most realistic approach.
Although the research summarized above shows early diagnosis and prevention of dementia eminently feasible as well as cost-effective, public understanding lags behind the research, delaying implementation of diagnostic and prevention technologies. Rather than requiring universal dementia checkups, a policy might begin by first publicizing that prevention is possible but after-the-fact cure is not, advising that citizens apply for their own risk-checks using the methods above. With a prevalence rate of 20% among those aged 65 and over, dementia imposes burdens on individuals, carers (especially family members), companies employing professional carers, and all taxpayers (the public). It is in the public interest that the state should subsidize costs for early salivary, urinary, fecal, or smartphone camera detection of dementia. It would be easy to add these tests into standard screenings already conducted for driver’s licenses and periodic elder health-checks. Results could be managed within a Personal Health Record (PHR) data infrastructure, facilitating effective preventive intervention and coordination. Government policy should emphasize the mission of early detection and prevention of dementia, establishing a shared understanding among the public and policy actors.
Subsequently, if states were to subsidize CST, VR programs, and possibly supplements for those whose checkups place them in above average risk categories, this would provide a double motivation for people to ask for check-ups and begin preventive routines. AI may assist worldwide data gathering and comparison on diagnostic and therapeutic efficacy. Governments might also provide watchdog services to assure that private corporations do not bilk gullible elders for useless or overpriced supplements.
Japan’s government, for example, has stated the policy mission of realizing a society capable of preventing dementia by 2033. If a diagnostic-therapeutic policy suppressed dementia onset by even 10%, it could yield economic benefits of anywhere from 3 to 12 trillion yen in Japan alone, demonstrating outstanding cost-effectiveness. Conversely, if governments delay widespread implementation of available diagnostics, anti-Aβ pharmaceuticals remain the extremely expensive but not-very-effective after-the-fact fallback. For worldwide detection and prevention of dementia, governments should encourage research on readily available, inexpensive and noninvasive methods.
Limitations
This report is not a systematic review; rather it spans multiple recent systematic reviews and medical reports on each emerging technology. We acknowledge the need for further testing and confirmation of each of the methods proposed here; these are not final answers but may serve as possible examples of affordable non-invasive testing and treatment. Rather than arguing the details of particular diagnostics and therapies, this article recommends that this kind of approach to affordable non-invasive strategies should take highest priority in research and public health policies.
Conclusion
Unlike medical interventions requiring lengthy animal and clinical testing, non-invasive tests and supplements/interventions are already available, safe, and easily incorporated into daily life, without requiring lengthy interviews, nurse intervention, nor hospital appointments. Every delay in their implementation and dissemination costs billions of dollars per year to aging societies, and incalculable anxiety and suffering to people living with dementia. It behooves governments and insurers to promote public policies for affordable early detection and prevention of dementias, and to prioritise further research on such methods.
Declarations
- Funding Declaration
- No funding was received for conducting this study or preparing this manuscript.
- Declaration of authors’ contributions
- All authors contributed to the study conception and design. Carl Becker was responsible for Writing the original English draft. All three authors (Carl Becker, Shota Kaneda, and Ryutaro Tanimura) actively and significantly contributed to Methodology, Investigation, Data Collection, and Writing Review.
- Acknowledgments/Disclosures
- The authors initiated this study for a Science for Re-designing Policy (SciRex) conference at the National Graduate Institute for Policy Studies in Tokyo in late 2025, conducted by the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT).
- Conflict of Interest
- The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The Japanese Ministry of Education, Culture, Sports, Science and Technology had no role in the design of the study, in the collection, analyses, or interpretation of data, nor in the writing or decision to publish the manuscript.
- Ethical Approval
- The Kyoto University Ethics Review Board concluded that Ethics Review and Informed Consent are inapplicable, as no humans nor animals were used, and all the information researched and presented here is publicly available.
- Other Statements and Declarations
- Not Applicable.
References
- https://www.who.int/news-room/fact-sheets/detail/dementia, accessed March 15, 2026.
- Hiyoshi-Taniguchi K, Becker CB, Kinoshita A. What behavioral and psychological symptoms of dementia affect caregiver burnout? Clin Gerontologist 2018; 41 (3): 1-6. doi: 10.1080/07317115.2017.1398797.
- Hiyoshi-Taniguchi K, Becker CB, Kinoshita A. Social workers can use sense of coherence to predict burnout of end-of-life caregivers. British Jl Social Work 2014; 44 (8): 2360–2374. doi: 10.1093/bjsw/bct086.
- Figure 10.7. https://www.oecd.org/en/publications/health-at-a-glance-2025_8f9e3f98-en/full-report/dementia_8b14a2ea.html, accessed March 15, 2026.
- https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/, accessed March 15, 2026.
- Price PU, Heggie R, Moriguti JC, Pereira LRL. Evaluating the cost-effectiveness of pharmacological therapy in Alzheimer Disease in Brazil. Value Health Regional Issues. 2025; 49: 1-8. doi:10.1016/j.vhri.2025.101130.
- Bakhtiari S, Moghadam NB, Ehsani M, Mortazavi H, Sabour S, Bakhshi M. Can salivary acetylcholinesterase be a diagnostic biomarker for Alzheimer? J. Clin. Diagnost. Res. 2017; 11 (1): ZC58–ZC60. doi:10.7860/JCDR/2017/21715.9192.
- Farah R, Haraty H, Salame Z, Fares Y, Ojcius DM, Sadier NS. Salivary biomarkers for the diagnosis and monitoring of neurological diseases. Biomed. J. 2018; 41 (2): 63–87. https://doi.org/10.1016/j.bj.2018.03.004.
- Carro E, Bartolomé F, Bermejo-Pareja F, et al. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. Alzheimer’s & Dementia (Amsterdam). 2017; 8: 131-138. doi:10.1016/j.dadm.2017.04.002.
- Hammerschlag BL, Butts B, Likos KD, Verble DD, Nimmagadda N, Wharton W. Pilot: Salivary lactoferrin as a potential preclinical Alzheimer’s disease biomarker. Journal of Alzheimer’s Disease Reports. 2025; 9. doi:10.1177/25424823251409391.
- Orive G, Lopera F, Carro E. Saliva is a good candidate to be the new gold-standard sample for neurodegenerative diseases. Journal of Alzheimer’s Disease. 2022; 87 (4): 1497-1501. doi:10.3233/JAD-220144.
- Saiyed N, Yilmaz A, Vishweswariah S, et al. Urinary cytokines as potential biomarkers of mild cognitive impairment and Alzheimer’s Disease. Journal of Alzheimer’s Disease Reports. 2023; 7 (1): 649–657. doi: 10.3233/ADR-220081.
- Kang MM, Wang R. Perspectives on urine AD7c-NTP: A biomarker for Alzheimer’s Disease. Urine. 2022; 4: 3-5. DOI:10.1016/j.urine.2022.01.001
- Gao C, Li B, He Y, et al. Early changes of fecal short-chain fatty-acid levels in patients with mild cognitive impairments. CNS Neuroscience & Therapeutics. 2023; 29 (11): 3657-3666. doi:10.1111/cns.14252.
- Saji N, Murotani K, Hisada T, et al. Relationship between dementia and gut microbiome-associated metabolites: A cross-sectional study in Japan. Sci Rep. 2020; 10 (8088): 1-10. doi:10.1038/s41598-020-65196-6.
- https://www.tobii.com/resource-center/learn-articles/4-methods-to-assess-alzheimers-with-eye-tracking accessed March 15, 2026.
- Hannonen S, Andberg S, Kärkkäinen, V, et al. Eye-tracking saccade parameters reveal early cognitive decline in relation to clinical dementia rating: Sum of boxes scores. Jl Alzheimer’s Disease. 2026; 109 (3): 1371-1379. doi:10.1177/13872877251406625.
- Parra, M. A., Granada, J., & Fernández, G. Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer's Disease. Alzheimer's & Dementia (Amsterdam). 2022;14 (1): e12386. doi: 10.1002/dad2.12386.
- Bott NT, Madero EN, Glenn JM, et al., Device-embedded cameras for eye tracking-based cognitive assessment: Implications for teleneuropsychology. Telemedicine and e-Health. 2020; 26 (4): 477-481. doi: 10.1089/tmj.2019.0039.
- Li Q, Yan J, Ye J, et al. Construction of a prediction model for Alzheimer's disease using an AI-driven eye-tracking task on mobile devices. Aging Clin Exp Res. 2024; 37 (9): 1-12. doi: 10.1007/s40520-024-02882-9.
- Shah HA, Khalil S, Andberg S, Koivisto AM, Bednarik R. Eye tracking based detection of mild cognitive impairment: A review. Information Fusion. 2025; 122. doi:10.1016/j.inffus.2025.103202.
- Eaglestone G, Gkaintatzi E, Jiang H, Stoner C, Pacella R, McCrone P. Cost-Effectiveness of non-pharmacological interventions for mild cognitive impairment and dementia: A systematic review of economic evaluations and a review of reviews. PharmacoEconomics—Open. 2023; 7 (6): 887-914. doi:10.1007/s41669-023-00440-z.
- Jiménez-Palomares M, Montero-Barrero O, Garrido-Ardila EM, Gibello-Rufo A, González-Sánchez B, Rodríguez-Mansilla J. Cognitive stimulation in older adults with dementia: A systematic review. Jl Clinical Medicine. 2025; 14 (20): 7225. doi:10.3390/jcm14207225..
- D'Amico F, Rehill A, Knapp M, et al. Maintenance cognitive stimulation therapy: An economic evaluation within a randomized controlled trial. J Am Med Dir Assoc. 2015; 16 (1): 63-70. doi:10.1016/j.jamda.2014.10.020.
- Seike A, Sumigaki C, Takeuchi S. et al. Efficacy of group-based multi-component psycho-education for caregivers of people with dementia: A randomized controlled study. Geriatr Gerontol Int. 2021; 21 (7): 561-567. doi:10.1111/ggi.14175.
- Coe NB, Miller KEM, Sun C, et al. Impact of cognitive training on claims-based diagnosed dementia over 20 years: Evidence from the ACTIVE study. Alzheimer's & Dementia (NY). 2026; 12 (1): e70197. doi:10.1002/trc2.70197.
- Kim, S. et al. (2026), Policies for people with dementia across OECD countries, OECD Health Working Papers, No. 190, OECD Publishing, Paris, https://doi.org/10.1787/e41e6eaa-en.
- Kang JM, Kim N, Lee SY, et al. Effect of cognitive training in fully immersive virtual reality on visuospatial function and frontal-occipital functional connectivity in predementia: A Randomized Controlled Trial. J Med Internet Res. 2021; 23 (5): e24526. doi:10.2196/24526.
- Tominari M, Uozumi R, Becker CB, Kinoshita A. Reminiscence therapy using virtual reality technology affects cognitive function and subjective well-being in older adults with dementia. Cogent Psychology. 2021; 8 (1). doi:10.1080/23311908.2021.1968991.
- Porras-Garcia B, Rojas-Rincón J, Adams A, Garolera M, Chang R. Immersive virtual reality cognitive training for improving cognition and depressive symptoms among older adults: Current evidence and future recommendations. Cyberpsychology, Behavior, and Social Networking. 2024; 27 (10): 692-703. doi:10.1089/cyber.2024.0090.
- Yang Q, Zhang L, Chang F, Yang H, Chen B, Liu Z. Virtual reality interventions for older adults with mild cognitive impairment: Systematic review and meta-analysis of Randomized Controlled Trials. Journal of Medical Internet Research. 2025; 27: e59195. doi:10.2196/59195.
- Buele J, Varela-Aldás JL, Palacios-Navarro G. Virtual reality applications based on instrumental activities of daily living (iADLs) for cognitive intervention in older adults: A systematic review. J NeuroEngineering Rehabil. 2023; 20: 168. .
- Tziraki C, Berenbaum R, Gross D, Abikhzer J, Ben-David BM. Designing serious computer games for people with moderate and advanced dementia: Interdisciplinary theory-driven pilot study. JMIR Serious Games. 2017; 5 (3): e16. doi:10.2196/games.6514.
- Sala-Vila A, Tintle N, Westra J, Harris, WS. Plasma Omega-3 fatty acids and risk for incident dementia in the UK Biobank Study: A closer look. Nutrients. 2023; 15 (23): 4896. doi: 10.3390/nu15234896.
- Białecka-Dębek A, Granda D, Pietruszka B. The role of docosahexaenoic acid (DHA) in the prevention of cognitive impairment in the elderly. Postępy Higieny i Medycyny Doświadczalnej. 2021; 75 (1): 345-361 doi:10.5604/01.3001.0014.8986.
- Sala-Vila A, Tintle N, Westra J, Harris WS. Blood Omega-3 is inversely related to risk of early-onset dementia. Clin Nutr. 2026; 57:106559. doi:10.1016/j.clnu.2025.106559.
- Hamdy SM, Mekheimer MB, Youness ER. et al. The ameliorative effect of sodium butyrate alone or combined with vitamin E on oxidative stress and neurodegeneration in an experimental model of Alzheimer’s disease. Comp Clin Pathol. 2025; 34: 1165–1177. doi:10.1007/s00580-025-03725-3.
- Fernando WMADB, Martins IJ, Morici M, et al. sodium butyrate reduces brain amyloid-β levels and improves cognitive memory performance in an Alzheimer's Disease transgenic mouse model at an early disease stage. Journal of Alzheimer's Disease. 2020; 74 (1): 91-99. doi:10.3233/JAD-190120.
- Tu J, Zhang J, Chen G. Higher dietary butyrate intake is associated with better cognitive function in older adults: Evidence from a cross-sectional study. Front. Aging Neurosci. 2025; 17: 1522498. doi:10.3389/fnagi.2025.1522498.
- Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer’s disease in elderly patients with bipolar disorder. Br. J. Psychiatry. 2007; 190: 359–360. doi:10.1192/bjp.bp.106.029868.
- Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr. Alzheimer Res. 2013; 10 (1): 104–107. doi: 10.2174/1567205011310010014.
- Shim SS, Berglund K, Yu SP. Lithium: An old drug for new therapeutic strategy for Alzheimer’s Disease and related dementia. Neurodegener Dis. 2023; 23 (1-2): 1-12. doi.org/10.1159/000533797
- Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3 alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature. 2003; 423, 435–439. doi:10.1038/nature01640
- Pacholko AG, Bekar LK. Lithium orotate: A superior option for lithium therapy? Brain and Behavior. 2021; 11 (8): e2262. doi:10.1002/brb3.2262.
- Pacholko AG, Bekar LK. Different pharmacokinetics of lithium orotate inform why it is more potent, effective, and less toxic than lithium carbonate in a mouse model of mania. Journal of Psychiatric Research, 2023; 164:192-201. doi:10.1016/j.jpsychires.2023.06.012.
- Chen S, Underwood BR, Jones PB, Lewis JR, Cardinal RN. Association between lithium use and the incidence of dementia and its subtypes: A retrospective cohort study. PLoS Med. 2022; 19(3): e1003941. doi:10.1371/journal.pmed.1003941.
- Matsunaga S, Kishi T, Annas P, Basun H, Hampel H, and Iwata N. Lithium as a treatment for Alzheimer’s disease: a systematic review and meta-analysis. J. Alzheimers Dis. 2015; 48, 403–410. doi:10.3233/jad-150437.
- Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: Randomised clinical trial. British Journal of Psychiatry. 2019; 215 (5): 668-674. doi:10.1192/bjp.2019.76.
- Kishi T, Matsunaga S, Saito Y, Iwata S. Lithium for Alzheimer’s Disease: Insights from a meta-analysis. Neuroscience & Biobehavioral Reviews. 2026; 180. doi:10.1016/j.neubiorev.2025.106458.
- Lu QY, Lv HJ, Liu XT, Zang LL, Zhang Y, Meng QH. Lithium therapy’s potential to lower dementia risk and the prevalence of Alzheimer’s Disease: A meta-analysis. Eur Neurol. 2024; 87 (2): 93–104. doi:10.1159/000538846.
- Terao I, Honyashiki M, Inoue T. Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer’s disease: A systematic review and network meta-analysis. Ageing Res. Rev. 2022; 81: 101709. doi:10.1016/j.arr.2022.101709.
- Terao I, Kodama W. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer’s disease: a systematic review and network meta-analysis. Ageing Res. Rev. 2024; 94: 102203. doi:10.1016/j.arr.2024.102203.
- Aron L, Ngian ZK, Qiu C, et al. Lithium deficiency and the onset of Alzheimer’s disease. Nature. 2025; 645: 712–721. doi:10.1038/s41586-025-09335-x.
- https://hms.harvard.edu/news/could-lithium-explain-treat-alzheimers-disease accessed March 15, 2026.
- Bush AI. Does lithium deficiency contribute to Alzheimer's disease? Nature. 2025; 645 (8081): 593-594. doi:10.1038/d41586-025-02255-w.
- Kessing LV, Gerds TA, Knudsen NN, et al. Association of lithium in drinking water with the incidence of dementia. JAMA Psychiatry. 2017; 74 (10): 1005–1010. doi:10.1001/jamapsychiatry.2017.2362.
- Strawbridge R, Young AH. Lithium: how low can you go? Int Jl Bipolar Disorders. 2024; 12 (1): 4. doi: 10.1186/s40345-024-00325-y.
- 2025 Alzheimer’s disease facts and figures, Alzheimer’s & Dementia. 2025 Apr 29; 21 (4): e70235 doi: 10.1002/alz.70235 accessed March 15, 2026.
Article information
Authors
- Carl BeckerCenter for iPS Cell Research and Application, Kyoto University, Kyoto, Japan 606-8507Corresponding author · [email protected]
- Ryutaro TanimuraNational Graduate Institute for Policy Studies, Tokyo, Japan 106-8677
- Shota KanedaDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan 113-0033
How to cite
Becker, C., Tanimura, R., et al., 2026. New Cost-Effective Technologies for Prediction and Prevention of Dementia. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0625
Record
- Journal
- Medical Research Archives
- Issue
- Vol 14 No 10 (2026)
- Section
- Policy Articles
- Published
- 31 October 2026
- ISSN
- 2375-1924
- Downloads
- 67
Copyright and licence
Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.